JOURNAL OF PHARMA INSIGHTS AND RESEARCH

REVIEW ARTICLE

Capecitabine: A Promising Anticancer Drug

Akshada M. Vanave[1], Chougle N.B[2], Kamble J.R[3], Salokhe P.A.[3]

[1]*Student, Ashok Rao Mane Institute of Pharmacy Ambap, Kolhapur, India*
[2]*Principal and Professor, Ashok Rao Mane Institute of Pharmacy Ambap, Kolhapur, India*
[3]*Assistant Professor, Ashok Rao Mane Institute of Pharmacy Ambap, Kolhapur, India*

Publication history: Received on 10thJanuary; Revised on 28th January; Accepted on 1st February

Article DOI: 10.5281/zenodo.10625684

Abstract:
Capecitabine, a prodrug of 5-fluorouracil (5-FU), has emerged as a cornerstone in the treatment of various solid tumors, particularly colorectal, breast, and gastric cancers. Its unique mechanism of action involves conversion into 5-FU preferentially in tumor cells through a series of metabolic steps. This selective activation minimizes systemic toxicity while maximizing anticancer efficacy. In addition to its role as a single-agent therapy, capecitabine has demonstrated substantial efficacy in combination regimens, further enhancing its versatility in clinical practice. This review provides an overview of the pharmacology, clinical efficacy, and safety profile of capecitabine across different malignancies. Furthermore, the evolving trends of precision oncology and the potential implications of biomarker-driven approaches in optimizing capecitabine-based therapies are explained. Despite its proven efficacy, capecitabine is associated with manageable adverse effects, including hand-foot syndrome, gastrointestinal disturbances, and myelosuppression. Strategies for mitigating these toxicities are also explored. Additionally, the review highlights ongoing research efforts aimed at elucidating predictive biomarkers for patient selection and identifying novel therapeutic combinations to further improve outcomes. Overall, capecitabine stands as a potential candidate for personalized treatment and could be a significant anticancer drug in the era of precision medicine.

Keywords: Capecitabine; Anticancer drug; Precision oncology; 5-fluorouracil; Biomarkers

1. Introduction

Cancer remains one of the most formidable challenges to public health worldwide, with its relentless impact on millions of lives necessitating the continuous exploration and refinement of therapeutic strategies. Among the arsenal of anticancer agents, capecitabine has emerged as a cornerstone in the treatment landscape, offering a potent and versatile option for various solid tumors. This review aims to provide a comprehensive overview of capecitabine, spanning its pharmacology, clinical efficacy, safety profile, and evolving role in the era of precision oncology. Capecitabine, an orally administered prodrug, represents a pivotal advancement in the pharmacotherapeutic approach to cancer management. [1,2] It is enzymatically converted into 5-fluorouracil (5-FU) in tumor tissues, exploiting the higher expression of thymidine phosphorylase in malignant cells. This metabolic activation pathway confers a preferential cytotoxic effect on cancer cells while minimizing systemic toxicity, a hallmark of traditional 5-FU-based regimens. Such selective targeting underscores the rationale behind the widespread adoption of capecitabine across various malignancies, including colorectal, breast, and gastric cancers. [3,4]

The clinical efficacy of capecitabine spans multiple fronts, with robust evidence supporting its role as both a single-agent therapy and in combination regimens. In colorectal cancer, capecitabine has demonstrated non-inferiority to infusional 5-FU/leucovorin in adjuvant settings and significant improvements in overall survival when combined with oxaliplatin in advanced disease. Similarly, in breast cancer, capecitabine has established itself as a key component in the management of metastatic disease, particularly in anthracycline- and taxane-resistant cases. Furthermore, its efficacy in gastric cancer, either as monotherapy or in combination with platinum-based regimens, has been validated in multiple clinical trials. Despite its efficacy, capecitabine is not devoid of adverse effects, with hand-foot syndrome, gastrointestinal disturbances, and myelosuppression representing notable toxicities. However, these are generally manageable with dose adjustments, supportive care measures, and proactive monitoring. Strategies aimed at optimizing the therapeutic index of capecitabine, including dose fractionation schedules and pharmacogenomic considerations, continue to evolve, further enhancing its clinical utility. [5] The advent of precision oncology has ushered in a new era of personalized cancer treatment, with biomarker-driven approaches playing a pivotal role in treatment selection and prognostication. Capecitabine, with its distinct mechanism of action and well-defined pharmacokinetic profile, presents an intriguing substrate for biomarker exploration. Various molecular markers, including thymidine phosphorylase expression and genetic polymorphisms in drug-metabolizing enzymes, have been proposed as potential predictors of response and toxicity to capecitabine-based therapies. [6]

* Corresponding author: Akshada M. Vanave

In light of these developments, this review aims to synthesize the existing body of evidence surrounding capecitabine, elucidating its pharmacological underpinnings, clinical efficacy, safety profile, and the evolving landscape of precision oncology.

2. Pharmacology of Capecitabine

Capecitabine, an orally administered fluoropyrimidine carbamate, represents a prodrug that undergoes enzymatic conversion to its active form, 5-fluorouracil (5-FU), within tumor tissues. The metabolic activation of capecitabine primarily occurs through a series of three enzymatic steps. First, in the liver, carboxylesterase enzymes catalyze the conversion of capecitabine to 5'-deoxy-5-fluorocytidine (5'-DFCR). [7] Subsequently, cytidine deaminase converts 5'-DFCR to 5'-deoxy-5-fluorouridine (5'-DFUR). Finally, thymidine phosphorylase (TP), an enzyme with higher expression in tumor tissues compared to normal tissues, catalyzes the conversion of 5'-DFUR to the active cytotoxic agent, 5-FU. Once activated, 5-FU exerts its anticancer effects through multiple mechanisms. It functions as a nucleotide analog, incorporating into RNA and DNA, thereby disrupting nucleic acid synthesis and impairing DNA repair mechanisms. Moreover, 5-FU inhibits thymidylate synthase, an enzyme essential for DNA synthesis, leading to a depletion of thymidine nucleotides and subsequent DNA strand breaks. Additionally, 5-FU disrupts RNA processing and protein synthesis, further contributing to its cytotoxic effects on cancer cells. [8]

The preferential activation of capecitabine into 5-FU within tumor tissues offers several advantages over traditional intravenous 5-FU-based regimens. Firstly, the conversion of capecitabine to 5-FU occurs predominantly in tumor cells due to the higher expression of TP, resulting in enhanced selectivity and reduced systemic toxicity. This selective activation also allows for sustained intratumoral concentrations of 5-FU, prolonging its cytotoxic effects while minimizing exposure to normal tissues. Furthermore, the oral formulation of capecitabine offers convenience and flexibility in administration, facilitating outpatient treatment and improving patient adherence compared to intravenous regimens.[9]

The pharmacokinetic profile of capecitabine is characterized by rapid absorption from the gastrointestinal tract, followed by extensive metabolism predominantly in the liver. The major metabolites include 5'-DFUR and α-fluoro-β-alanine (FBAL), with only a small fraction of the administered dose excreted unchanged in the urine. Capecitabine exhibits linear pharmacokinetics over a wide range of doses, with predictable exposure-response relationships observed in clinical trials. [10]

3. Clinical efficacy and safety profile

Capecitabine has demonstrated significant clinical efficacy across a spectrum of solid tumors, including colorectal, breast, gastric, and pancreatic cancers, both as a single-agent therapy and in combination regimens. In colorectal cancer, capecitabine has been extensively studied in both the adjuvant and metastatic settings. In landmark trials such as X-ACT (Xeloda in Adjuvant Colon Cancer Therapy) and NO16968, capecitabine has shown non-inferiority to infusional 5-fluorouracil (5-FU)/leucovorin in terms of disease-free survival and overall survival in patients with stage III colon cancer.[11] Additionally, in the metastatic setting, capecitabine-based regimens, such as CAIRO (Capecitabine, Irinotecan, and Oxaliplatin) and XELOX (capecitabine plus oxaliplatin), have demonstrated efficacy comparable to or superior to traditional 5-FU-based combinations, with manageable toxicity profiles. In breast cancer, capecitabine plays a crucial role in the management of metastatic disease, particularly in anthracycline- and taxane-resistant cases. Studies such as the TBP (Taxotere, Bevacizumab, and capecitabine) trial and the BEAT (Bevacizumab and capecitabine versus capecitabine alone in elderly patients with metastatic breast cancer) trial have shown improved progression-free survival and overall response rates with the addition of capecitabine to standard chemotherapy regimens. Furthermore, in the adjuvant setting, capecitabine has demonstrated efficacy in high-risk breast cancer subtypes, such as triple-negative breast cancer, warranting further investigation in this population.[12]

In gastric cancer, capecitabine has emerged as a key component in the management of advanced disease, either as monotherapy or in combination with platinum-based regimens. The REAL-2 (Randomised ECF vs. Modified ECF) trial demonstrated non-inferiority of capecitabine compared to infusional 5-FU in combination with platinum-based chemotherapy in patients with advanced gastroesophageal cancer, with comparable efficacy and improved safety profile. Additionally, the TOXAG study showed improved tolerability of capecitabine-based regimens compared to infusional 5-FU, further supporting its use in this setting. Despite its efficacy, capecitabine is associated with a spectrum of adverse effects, most commonly hand-foot syndrome (palmar-plantar erythrodysesthesia), diarrhea, nausea, vomiting, and myelosuppression. [13] These toxicities are generally manageable with dose adjustments, supportive care measures, and proactive management strategies. Hand-foot syndrome, characterized by erythema, swelling, and desquamation of the palms and soles, represents a unique toxicity of capecitabine therapy and may require dose modifications or treatment interruptions to alleviate symptoms.[14]

Capecitabine offers significant clinical efficacy across multiple solid tumors, with a manageable safety profile compared to traditional intravenous chemotherapy regimens. Understanding the efficacy and safety profile of capecitabine is essential for optimizing its use in clinical practice and improving outcomes for patients with cancer. Ongoing research efforts aimed at elucidating predictive

biomarkers and identifying novel therapeutic combinations will further enhance the role of capecitabine in the contemporary management of solid tumors. [15]

4. Role of Capecitabine in Precision Oncology: Biomarker-driven Approaches

Precision oncology aims to tailor cancer treatment strategies based on individual patient characteristics, including molecular biomarkers, to optimize therapeutic outcomes. Capecitabine, with its distinct mechanism of action and well-defined pharmacokinetic profile, presents an intriguing substrate for biomarker exploration and personalized treatment approaches. One of the key biomarkers under investigation in the context of capecitabine therapy is thymidine phosphorylase (TP), the enzyme responsible for converting capecitabine into its active metabolite, 5-fluorouracil (5-FU). [16] Elevated TP expression in tumor tissues has been associated with increased intratumoral levels of 5-FU and improved response rates to capecitabine-based regimens. Conversely, low TP expression may confer resistance to capecitabine therapy, highlighting its potential utility as a predictive biomarker for treatment response.Genetic polymorphisms in drug-metabolizing enzymes involved in the activation and metabolism of capecitabine have also garnered attention as potential biomarkers of treatment outcomes. Variants in genes encoding enzymes such as cytidine deaminase (CDA) and dihydropyrimidine dehydrogenase (DPD) may influence the pharmacokinetics and toxicity profile of capecitabine, thereby impacting treatment efficacy and tolerability. For instance, patients carrying certain DPD variants may be at increased risk of developing severe myelosuppression or hand-foot syndrome, necessitating dose adjustments or alternative treatment strategies. Beyond pharmacogenomic considerations, molecular profiling of tumor tissue may offer valuable insights into the underlying biology of capecitabine-responsive tumors and identify potential therapeutic targets for combination therapies. Biomarkers such as microsatellite instability (MSI) and HER2/neu amplification have been implicated in the sensitivity of certain tumor types to fluoropyrimidine-based therapies, including capecitabine. Integration of molecular profiling data with clinical parameters may facilitate the identification of patient subpopulations most likely to benefit from capecitabine-based treatments. [17]

The advent of liquid biopsy techniques, such as circulating tumor DNA (ctDNA) analysis, offers a non-invasive means of monitoring treatment response and detecting emerging resistance mechanisms in real-time. Serial monitoring of ctDNA levels and mutational profiles may enable early identification of treatment resistance and inform timely treatment modifications or alternative therapeutic strategies. Biomarker-driven approaches hold promise for optimizing capecitabine-based treatments in the era of precision oncology. Integration of molecular biomarkers, pharmacogenomic data, and liquid biopsy techniques into clinical practice may enable more tailored and effective therapeutic strategies, ultimately improving outcomes for patients with cancer. Further research efforts are warranted to validate and refine biomarker-driven approaches and realize the full potential of precision medicine in oncology [18]

5. Management of adverse effects associated with capecitabine therapy

Capecitabine, like many chemotherapeutic agents, is associated with a spectrum of adverse effects, ranging from mild to potentially severe. Effective management of these adverse effects is essential to ensure patient comfort, treatment adherence, and optimal therapeutic outcomes. [6, 8, 9, 19]

5.1. Hand-Foot Syndrome (Palmar-Plantar Erythrodysesthesia)

Hand-foot syndrome is one of the most common adverse effects of capecitabine therapy, characterized by erythema, swelling, and desquamation of the palms and soles. To manage hand-foot syndrome, patients should be advised to avoid exposure to extreme temperatures and friction, wear comfortable and well-fitting shoes, and use moisturizers to keep the skin hydrated. Dose reductions or treatment interruptions may be necessary in cases of severe or persistent symptoms.

5.2. Gastrointestinal Disturbances

Diarrhea, nausea, and vomiting are frequently reported adverse effects of capecitabine therapy. Prophylactic antiemetic medications, such as serotonin receptor antagonists or neurokinin-1 receptor antagonists, may help alleviate nausea and vomiting. Anti-diarrheal medications, such as loperamide, can be used to manage diarrhea, with dose adjustments or treatment interruptions considered for severe or persistent cases.

5.3. Myelosuppression

Capecitabine can cause bone marrow suppression, leading to neutropenia, thrombocytopenia, and anemia. Regular monitoring of complete blood counts is essential during capecitabine therapy, with dose adjustments or treatment delays implemented as necessary based on hematologic toxicity. Granulocyte colony-stimulating factors (G-CSFs) may be considered to reduce the risk of febrile neutropenia in high-risk patients.

5.4. Fatigue

Cancer-related fatigue is a common adverse effect experienced by patients undergoing capecitabine therapy. Strategies to manage fatigue include adequate rest, maintaining a balanced diet, regular physical activity, and psychosocial support. Patients should be encouraged to communicate any significant changes in energy levels or fatigue to their healthcare providers.

5.5. Hepatotoxicity

Capecitabine may rarely cause hepatotoxicity, manifesting as elevations in liver function tests (e.g., alanine aminotransferase, aspartate aminotransferase). Regular monitoring of liver function tests is recommended during capecitabine therapy, with dose adjustments or treatment discontinuation considered for significant hepatic dysfunction.

5.6. Other Adverse Effects

Additional adverse effects associated with capecitabine therapy include dermatologic reactions (e.g., rash, alopecia), cardiovascular events (e.g., angina, myocardial infarction), and mucositis. Symptomatic management of these adverse effects may involve topical corticosteroids for dermatologic reactions, supportive care measures for cardiovascular events, and oral rinses or topical analgesics for mucositise [20]

6. Future perspectives

As research in oncology continues to advance, several future perspectives and emerging strategies hold promise for optimizing capecitabine-based treatments and improving outcomes for patients with cancer. [4,5, 21]

6.1. Biomarker-guided Treatment Selection

Further elucidation of predictive biomarkers for capecitabine response and toxicity will facilitate more personalized treatment approaches. Integration of molecular profiling data, pharmacogenomic considerations, and novel imaging techniques may enable the identification of patient subpopulations most likely to benefit from capecitabine-based therapies, leading to improved response rates and reduced toxicity.

6.2. Targeted Drug Delivery Systems

Development of targeted drug delivery systems for capecitabine may enhance tumor specificity, prolong drug exposure, and minimize systemic toxicity. Nanoparticle-based formulations, liposomal encapsulation, and prodrug conjugates represent promising strategies for optimizing the pharmacokinetic properties of capecitabine and enhancing its therapeutic efficacy in solid tumors.

6.3. Combination Therapies

Exploration of synergistic interactions between capecitabine and other anticancer agents holds potential for improving treatment outcomes and overcoming resistance mechanisms. Combinatorial approaches incorporating targeted therapies, immunotherapies, and antiangiogenic agents may enhance the cytotoxic effects of capecitabine, circumvent resistance pathways, and broaden its applicability across different tumor types.

6.4. Immunomodulatory Effects

Emerging evidence suggests that capecitabine may exert immunomodulatory effects beyond its direct cytotoxic activity. Preclinical studies have demonstrated enhanced antitumor immune responses following capecitabine treatment, including activation of cytotoxic T cells and modulation of the tumor microenvironment. Further investigation into the immunomodulatory properties of capecitabine and its potential synergies with immunotherapy approaches may uncover novel therapeutic strategies for enhancing antitumor immune responses and improving treatment outcomes.

6.5. Liquid Biopsy and Minimal Residual Disease Monitoring

Integration of liquid biopsy techniques, such as circulating tumor DNA (ctDNA) analysis, into routine clinical practice may enable real-time monitoring of treatment response, detection of minimal residual disease, and early identification of treatment resistance. Serial monitoring of ctDNA levels and mutational profiles may inform treatment decisions, guide treatment modifications, and facilitate timely intervention with alternative therapeutic strategies in patients receiving capecitabine-based treatments.

6.6. Patient-reported Outcomes and Supportive Care

Emphasis on patient-reported outcomes, quality of life assessments, and supportive care measures is essential to optimize the tolerability and adherence to capecitabine-based treatments. Multidisciplinary care teams, including oncologists, nurses, pharmacists,

and allied health professionals, play a pivotal role in providing comprehensive supportive care, addressing treatment-related adverse effects, and promoting patient-centered approaches to cancer care.

The key highlights of Capecitabine are enlisted in Table 1.

Table 1. Key aspects of Capecitabine in anticancer therapy

Aspect	Features of Capecitabine
Clinical Efficacy	Capecitabine demonstrates significant efficacy in various solid tumors, including colorectal, breast, and gastric cancers, as both single-agent and combination therapy.
Safety Profile	Adverse effects associated with capecitabine therapy include hand-foot syndrome, gastrointestinal disturbances, myelosuppression, and fatigue. However, these are generally manageable with dose adjustments and supportive care measures.
Role in Precision Oncology	Biomarker-driven approaches, such as TP expression and genetic polymorphisms, offer insights into treatment response and toxicity, facilitating personalized capecitabine-based therapies.
Management of Adverse Effects	Proactive management strategies for adverse effects, including dose adjustments, supportive care measures, and patient education, are essential to optimize tolerability and treatment adherence.
Future Perspectives and Emerging Strategies	Emerging strategies, such as targeted drug delivery systems, combination therapies, and immunomodulatory effects, hold promise for optimizing capecitabine-based treatments and improving outcomes.

7. Conclusion

Capecitabine has emerged as a pivotal anticancer agent with demonstrated efficacy across various solid tumors, offering a favorable balance of clinical benefit and tolerability. Its unique mechanism of action, selective activation in tumor tissues, and oral formulation have contributed to its widespread adoption in clinical practice. However, the management of capecitabine-associated adverse effects remains a clinical challenge, highlighting the importance of proactive monitoring and supportive care measures. With ongoing research efforts focused on elucidating predictive biomarkers, exploring novel treatment combinations, and optimizing drug delivery systems, the future of capecitabine-based treatments holds promise for further enhancing therapeutic outcomes and advancing precision oncology. By integrating these advancements into clinical practice and fostering collaboration across disciplines, we can continue to improve the efficacy, safety, and accessibility of capecitabine-based therapies and ultimately improve outcomes for patients with cancer.

References

[1] Pasumarthy SM, Pamujula B. Phytotherapeutic potential of natural polyphenols used in alleviating cancer: Short Communication. Journal of Pharma Insights and Research. 2023 Dec 1;1(2):047–52.

[2] Mannaa S, Lakshmia US, Racharlaa M, Sinhab P, Kanthala LK, Kumara SP. Bioadhesive HPMC gel containing gelatin nanoparticles for intravaginal delivery of tenofovir. Journal of Applied Pharmaceutical Science. 2016 Aug 30;6(8):022-9.

[3] Neelam VD, Neelam AKN. Solvent-free Mechanochemical synthesis of organic compounds: Review Article. Journal of Pharma Insights and Research. 2023 Dec 1;1(2):007–14.

[4] Reddy P, Pradeep S, Gopinath SM, Kollur SP, Shivamallu C. Plant Derived Bioactive Compounds, Their Anti-Cancer Effects as an Alternative Target Treatment Strategy for Breast Cancer: An Updated Overview. International Journal of Health and Allied Sciences. 2022;11(4):2.

[5] Bala A, Kar B, Haldar PK, Mazumder UK, Bera S. Evaluation of anticancer activity of Cleome gynandra on Ehrlich's Ascites Carcinoma treated mice. Journal of Ethnopharmacology. 2010;129(1):131–4.

[6] hakraborty SP. Medicinal plants and cervical cancer therapy: An overview. Journal of Pharmacognosy and Phytochemistry. 2019;8(3):3633–41.

[7] Luang-In V, Saengha W, Buranrat B, Nudmamud-Thanoi S, Narbad A, Pumriw S, et al. Cytotoxicity of lactobacillus plantarum KK518 isolated from Pak-Sian Dong (Thai Fermented Gynandropsis pentaphylla DC.) against HepG2, MCF-7 and HeLa cancer cells. Pharmacognosy Journal [Internet]. 2020 [cited 2024 Jan 19];12(5). Available from: https://phcogj.com/article/1231

[8] Neelam VD, Neelam AKN. Solvent-free Mechanochemical synthesis of organic compounds: Review Article. Journal of Pharma Insights and Research. 2023 Dec 1;1(2):007–14.

[9] Gupta MK, Neerupalli B, Shah K, Kumar A. A case report on drug-induced bullous pemphigoid in a cervical cancer patient undergoing chemotherapy: Case report. Journal of Pharma Insights and Research. 2023 Dec 18;1(2):206–9.

[10] Sarella PNK, Thammana PK. Potential applications of Folate-conjugated Chitosan Nanoparticles for Targeted delivery of Anticancer drugs. Research Journal of Pharmaceutical Dosage Forms and Technology. 2023;15(4):281–8.

[11] Varghese R, Salvi S, Sood P, Kulkarni B, Kumar D. Cubosomes in cancer drug delivery: A review. Colloid and Interface Science Communications. 2022;46:100561.

[12] Chen T, Ren L, Liu X, Zhou M, Li L, Xu J, et al. DNA nanotechnology for cancer diagnosis and therapy. International journal of molecular sciences. 2018;19(6):1671.

[13] da Silva Luz GV, Barros KVG, de Araújo FVC, da Silva GB, da Silva PAF, Condori RCI, et al. Nanorobotics in drug delivery systems for treatment of cancer: a review. J Mat Sci Eng A. 2016;6:167–80.

[14] Helmink BA, Khan MW, Hermann A, Gopalakrishnan V, Wargo JA. The microbiome, cancer, and cancer therapy. Nature medicine. 2019;25(3):377–88.

[15] Tharwat M, Sakr NA, El-Sappagh S, Soliman H, Kwak KS, Elmogy M. Colon cancer diagnosis based on machine learning and deep learning: Modalities and analysis techniques. Sensors. 2022;22(23):9250.

[16] Al-Sharif M, Awen B, Molvi K. Nanotechnology in cancer therapy: a review. J Chem. 2010;2(5):161–8.

[17] Guttikonda UG, Bhikari MK, Challa SP. Phytochemical and therapeutic potential of Chalcones in the treatment of Hyperlipidemia: Short Communication. Journal of Pharma Insights and Research. 2023 Dec 1;1(2):042–6.

[18] Gupta MK, Neerupalli B, Shah K, Kumar A. A case report on drug-induced bullous pemphigoid in a cervical cancer patient undergoing chemotherapy: Case report. Journal of Pharma Insights and Research. 2023 Dec 18;1(2):206–9.

[19] Guduru VSSSJ, Mulaparthi AR, Karumuri LC, Gariskuti H, Cholla SS. DNA Nanorobots In Cancer Therapy- A Review: Review article. Journal of Pharma Insights and Research. 2023 Dec 1;1(2):001–6.

[20] Lakshmi SS, Sarella PN, Adarsh K, Padmini PL, Kumar MV. Concurrent Diagnosis of Renal Calculi, Uterine Fibroids and Ovarian Cysts: A Complex Case Study. Journal of Clinical and Pharmaceutical Research. 2023 Oct 24:22-7.

[21] Harani A, VijayaRatnam J, Dipankar B, Kumar DS, Lalitha MB, Kumar SP. Molecular interaction studies of phosphatidylcholine as drug delivery substrate for asenapine maleate. Current Science. 2018 Aug 10;115(3):499-504.